A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men

Mikyas, Yeshi; Agodoa, Irene; Yurgin, Nicole

doi:10.1007/s40258-013-0078-1

Cited by 30 publications

(20 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in fracture rate is associated with great increases in mortality and healthcare costs, since treatment of fractures requires hospitalization and surgical interventions 16 . In our study, the largest percentage of respondents had vertebral fractures, which are difficult to treat and bear high treatment costs.…”

Section: Discussionmentioning

confidence: 99%

Drug-related problems in patients with osteoporosis

Ilić¹,

Bukumirić²,

Janković

2016

VSP

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Drug-related problems in patients with osteoporosis

Ilić¹,

Bukumirić²,

Janković

2016

VSP

View full text Add to dashboard Cite

show abstract

“…NIHR Journals Library www.journalslibrary.nihr.ac.uk Mikyas et al 131 reviewed treatment adherence in studies in male osteoporosis. Eighteen retrospective or prospective observational studies were included in the analysis.…”

Section: Assessment Of Clinical Effectivenessmentioning

confidence: 99%

Corrigendum: A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures

Davis

James

Sanderson

et al. 2018

Health Technol Assess

View full text Add to dashboard Cite

During the course of providing additional analyses for the National Institute for Health and Care Excellence Technology Appraisal Committee, two errors were identified in the data entered in the network meta-analysis that informed the cost-effectiveness analysis described in the original report. This corrigendum notice describes the errors identified and the impact of correcting these errors on the main analyses presented in the original report.

show abstract

“…Each man who screened positive with a particular strategy or who sustained a clinical fracture was assumed to be offered bisphosphonate therapy. In base-case analysis, we assumed that 50% of individuals were initially adherent and persisted with treatment; we assumed the remainder of individuals were noncompliant (24,25) and did not receive treatment benefit or incur treatment costs. For men with osteoporosis receiving bisphosphonate treatment, we assumed fracture risk reduction efficacy as reported in a meta-analysis of alendronate efficacy in men.…”

Section: Treatmentmentioning

confidence: 99%

Cost-Effectiveness of Osteoporosis Screening Strategies for Men

Nayak

Greenspan

2016

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Osteoporosis affects many men, with significant morbidity and mortality. However, the best osteoporosis screening strategies for men are unknown. We developed an individual-level state-transition cost-effectiveness model with a lifetime time horizon to identify the cost-effectiveness of different osteoporosis screening strategies for U.S. men involving various screening tests (dual-energy x-ray absorptiometry (DXA); the Osteoporosis Self-Assessment Tool (OST); or a fracture risk assessment strategy using age, femoral neck bone mineral density (BMD), and Vertebral Fracture Assessment (VFA)); screening initiation ages (50, 60, 70, or 80); and repeat screening intervals (5 years or 10 years). In base-case analysis, no screening was a less effective option than all other strategies evaluated; furthermore, no screening was more expensive than all strategies that involved screening with DXA or the OST risk assessment instrument, and thus no screening was “dominated” by screening with DXA or OST at all evaluated screening initiation ages and repeat screening intervals. Screening strategies that most frequently appeared as most cost-effective in base-case analysis and one-way sensitivity analyses when assuming willingness-to-pay of $50,000/QALY or $100,000/QALY included screening initiation at age 50 with the fracture risk assessment strategy and repeat screening every 10 years; screening initiation at age 50 with fracture risk assessment and repeat screening every 5 years; and screening initiation at age 50 with DXA and repeat screening every 5 years. In conclusion, expansion of osteoporosis screening for U.S. men to initiate routine screening at age 50 or 60 would be expected to be effective and of good value for improving health outcomes. A fracture risk assessment strategy using variables of age, femoral neck BMD, and VFA is likely to be the most effective of the evaluated strategies within accepted cost-effectiveness parameters. DXA and OST are also reasonable screening options, albeit likely slightly less effective than the evaluated fracture risk assessment strategy.

show abstract

A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men

Cited by 30 publications

References 68 publications

Drug-related problems in patients with osteoporosis

Drug-related problems in patients with osteoporosis

Corrigendum: A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures

Cost-Effectiveness of Osteoporosis Screening Strategies for Men

Contact Info

Product

Resources

About